Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trialShow others and affiliations
2024 (English)In: Leukemia, ISSN 0887-6924, E-ISSN 1476-5551, Vol. 38, no 4, p. 781-787Article in journal (Refereed) Published
Abstract [en]
Tyrosine kinase inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML) has become part of routine care for patients with a sustained deep molecular response (DMR). Approximately 50% experience a molecular relapse upon TKI cessation. Most of them quickly regain DMR upon TKI resumption. Whether these patients can achieve a second treatment-free remission (TFR) remains unclear. DAstop2 (ClinicalTrials.gov ID: NCT03573596) is a prospective study including patients with a failed first TFR attempt re-treated with any TKI for >= one year. Upon entering the study, patients received the TKI dasatinib for additional two years. Patients with sustained DMR for >= 1 year qualified for a second TKI stop. Ninety-four patients were included between Oct 2017-Dec 2021. At the time of data analysis, 62 patients had attempted a 2(nd) stop. After a median follow-up of 27 months from 2(nd) stop, TFR rates were 61, 56 and 46% at 6, 12 and 24 months respectively. No progression to advanced stage disease was seen and 87% had re-achieved MR4 within a median of 3 months from TKI re-initiation. In summary, we show that a 2(nd) TFR attempt after dasatinib treatment is safe, feasible and TFR rates seem in the range of those reported in trials of a first TKI stop.
Place, publisher, year, edition, pages
Springer Nature, 2024. Vol. 38, no 4, p. 781-787
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-202359DOI: 10.1038/s41375-024-02145-6ISI: 001188070700001PubMedID: 38278960Scopus ID: 2-s2.0-85183379737OAI: oai:DiVA.org:liu-202359DiVA, id: diva2:1851060
Note
Funding Agencies|Uppsala University
2024-04-122024-04-122025-02-25